← Back to Search

uEXPLORER/mCT for Coronavirus

N/A
Waitlist Available
Led By Guobao Wang, PhD
Research Sponsored by University of California, Davis
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
COVID-19 positive patients will have a previous positive COVID-19 test and radiographic findings, and/or a positive SARS-CoV-2 antibody test and be in early recovery.
First PET/CT visit needs to be within 8 weeks of COVID-19 diagnosis.
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 1 imaging visit up to 60 minutes
Awards & highlights

Study Summary

This trial is comparing COVID-19 patients to normal subjects, and measuring changes over time.

Eligible Conditions
  • Coronavirus

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~1 imaging visit up to 60 minutes
This trial's timeline: 3 weeks for screening, Varies for treatment, and 1 imaging visit up to 60 minutes for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
BAB permeability assessed
Secondary outcome measures
4 month follow-up PET/CT scan

Trial Design

1Treatment groups
Experimental Treatment
Group I: COVID-19 patientsExperimental Treatment1 Intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
uEXPLORER/mCT
2021
N/A
~20

Find a Location

Who is running the clinical trial?

University of California, DavisLead Sponsor
908 Previous Clinical Trials
4,704,102 Total Patients Enrolled
Guobao Wang, PhDPrincipal InvestigatorUniversity of California, Davis
2 Previous Clinical Trials
71 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
~3 spots leftby Mar 2025